Please ensure Javascript is enabled for purposes of website accessibility
Early Opportunities
Get in Before the Crowd

February 28, 2025

Sell Astera Labs (ALAB) and Cellebrite (CLBT)

Sell Astera Labs (ALAB) and Cellebrite (CLBT)

We’re going to make a few portfolio changes today given the shifty dynamics of this market.

First up, we’re going to let go of our half stake in Astera Labs (ALAB). The stock is trading near its 200-day moving average line and didn’t get any bump at all from Nvidia’s (NVDA) earnings. SELL HALF POSITION

We’re also going to let go of Cellebrite (CLBT) today due to risk in the federal market. This risk may be overblown, but I don’t see it evaporating in the near term, so it’ll likely keep a lid on CLBT’s performance. SELL

Elsewhere, I’m considering filling the second half of a few of our positions. But not today. We’ll see how the market acts next week now that the PCE inflation report (met consensus, which is good) is out of the way.

Watch List Update

I’m also going to tighten up the focus in our Watch List by dropping Alphabet (GOOG), Integer Holdings (ITGR), EVgo (EVGO) and NuScale Power (SMR) due to unimpressive performance lately.


Copyright © 2025. All rights reserved. Copying or electronic transmission of this information without permission is a violation of copyright law. For the protection of our subscribers, copyright violations will result in immediate termination of all subscriptions without refund. Disclosures: Cabot Wealth Network exists to serve you, our readers. We derive 100% of our revenue, or close to it, from selling subscriptions to our publications. Neither Cabot Wealth Network nor our employees are compensated in any way by the companies whose stocks we recommend or providers of associated financial services. Employees of Cabot Wealth Network may own some of the stocks recommended by our advisory services. Disclaimer: Sources of information are believed to be reliable but they are not guaranteed to be complete or error-free. Recommendations, opinions or suggestions are given with the understanding that subscribers acting on information assume all risks involved. Buy/Sell Recommendations: are made in regular issues, updates, or alerts by email and on the private subscriber website. Subscribers agree to adhere to all terms and conditions which can be found on CabotWealth.com and are subject to change. Violations will result in termination of all subscriptions without refund in addition to any civil and criminal penalties available under the law.


Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company’s long-term success. Accordingly, his research focuses on assessing the viability of management’s growth strategies, trends in addressable markets and achievement of major developmental milestones.